ReviewImmunotherapy2025
Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer.
Review in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes.Frontiers in medicine · 2026Review
- Psychological analysis of depression, anxiety, and quality of life in postoperative thyroid cancer patients: a narrative review.Thyroid research · 2025Review
- Multimodal spectrum of approach in poorly differentiated thyroid carcinoma (an updated analysis).Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic and poorly differentiated thyroid carcinomas are the two most aggressive forms of thyroid cancers and carry significant morbidity and mortality despite multimodal therapeutic approaches. Anaplastic thyroid carcinoma (ATC) and, to a lesser degree, poorly differentiated thyroid carcinoma (PDTC) have a high tumor mutation burden, and immunologically hot tumor microenvironment when compared to well-differentiated thyroid carcinomas. As such, immunotherapy, and in particular immune checkpoint inhibitors, have been hypothesized to be effective against these cancers. This review aims to explore the biological rationale for immunotherapy in dedifferentiated thyroid carcinomas and to summarize the current evidence underlying this treatment modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.